

IN THE CLAIMS

1(Previously Amended). A nona or decapeptide which appears in the sequence of Lactadherin (BA-46), which peptide is selected so as to promote effective binding to a MHC class 1 type molecule so as to elicit a CTL response.

Claims 2-15 (Cancelled)

16(Previously Amended). The peptide of claim 1 consisting of SEQ ID NOs: 35, 36, 37, 38, 39, 40, 41 or 41.

Claims 17-18 (Cancelled)

19(Previously Amended). The peptide of claim 1, wherein said peptide is derived from a mammal.

20(Previously Amended). The peptide of claim 19, wherein the mammal is a human or a rodent.

21(Previously Amended). The peptide of claim 1, wherein said peptide includes at least one non-natural modification.

Claim 22 (Cancelled)

23(Previously Amended). The peptide of claim 21, wherein said at least one modification is selected from the group consisting of peptoid modification, cyclic peptide modification, N terminus modification, C terminus modification, peptide bond modification, backbone modification and residue modification.

24(Previously Amended). A pharmaceutical composition

comprising, as an active ingredient, at least one peptide as set forth in claim 1 and a pharmaceutically acceptable carrier.

Claim 25 (Cancelled)

26(Previously Amended). The pharmaceutical composition of claim 24, wherein the composition is effective to inhibit cancer or cancer metastases.

27(Original). The pharmaceutical composition of claim 26, wherein said cancer is selected from the group consisting of breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach and head and neck cancer.

28(Original). The pharmaceutical composition of claim 26, wherein said cancer is a carcinoma.

29(Original). The pharmaceutical composition of claim 24, wherein the composition is a vaccine.

30(Previously Amended). A vaccine composition comprising, as an active ingredient, at least one peptide as set forth in claim 1 and a suitable carrier.

31(Previously Amended). The vaccine composition of claim 30, wherein said carrier is selected from the group consisting of a proteinaceous carrier to which said at least one peptide is linked, an adjuvant, a protein or a recombinant protein and an antigen presenting cell.

32(Previously Amended). The vaccine composition of claim 30, wherein the composition is effective to inhibit cancer

or cancer metastases.

33(Original). The vaccine composition of claim 32, wherein said cancer is selected from the group consisting of breast, bladder, prostate, pancreas, ovary, thyroid, colon, stomach and head and neck cancer.

34(Original). The vaccine composition of claim 32, wherein said cancer is a carcinoma.

Claims 35-43 (Cancelled)

44(Original). The peptide of claim 1, wherein the second residue and the end residue are neutral, hydrophobic and aliphatic.

45(Previously Amended). The pharmaceutical composition of claim 24 also comprising a peptide having a helper T cell epitope.

Claims 46-51 (Cancelled)

52(Previously Amended). A peptide which appears in the sequence of a tumor-associated antigen selected from the group consisting of Uroplakin (UP), Prostate specific antigen (PSA), Prostate specific membrane antigen (PSMA), Prostate acid phosphatase (PAP), Lactadherin (BA-46) and Mucin (MUC1) and Teratocarcinoma-derived growth factor (CRIPTO-1), the peptide consisting of 9 or 10 amino acid residues selected so as to promote effective binding to a MHC class 1 type molecule so as to elicit a CTL response.

53(Previously Added). The pharmaceutical composition of claim 26, wherein said cancer is breast cancer.

54(Previously Added). The vaccine composition of claim 32, wherein said cancer is breast cancer.

55(New). The peptide according to claim 16, consisting of SEQ ID NO:38.

56(New). The peptide according to claim 16, consisting of SEQ ID NO:39.

57(New). The peptide according to claim 16, consisting of SEQ ID NO:41.